During the last three months, 13 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $79.69, along with a high estimate of $100.00 and a low estimate of $46.00. Observing a downward trend, the current average is 7.24% lower than the prior average price target of…